Trials / Completed
CompletedNCT00782535
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH SINGLE DOSES OF CHF 4226 pMDI IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE A Multicenter, Randomized, Double-Blind,Placebo-Controlled, 5-Way Crossover Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the dose-response profile of peak and trough FEV1 after single dose administrations of carmoterol in patients with COPD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHF 4226 pMDI | Inhaled solution, single therapeutic dose |
| DRUG | CHF 4226 pMDI | Inhaled solution, single supratherapeutic dose |
| DRUG | Placebo | Inhaled solution, single dose of placebo |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-10-31
- Last updated
- 2019-11-06
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00782535. Inclusion in this directory is not an endorsement.